Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HMPL-760 planned dose 1 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| HMPL-760 planned dose 1 | DRUG | HMPL-760 planned dose 1 daily (QD) orally |
| R-GemOx | DRUG | R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle. |
| HMPL-760 placebo planned dose 1 | DRUG | HMPL-760 placebo planned dose 1 daily (QD) orally |
| HMPL-760 planned dose 2 | DRUG | HMPL-760 planned dose 2 daily (QD) orally |
| HMPL-760 placebo planned dose 2 | DRUG | HMPL-760 placebo planned dose 2 daily (QD) orally |
HMPL-760 planned dose 1 is an investigational small molecule being studied for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). It is currently in Phase 2 clinical development as a monotherapy or in combination with other agents for patients whose disease has not responded to prior therapy or has returned after treatment.
HMPL-760 planned dose 1 is being developed by HUTCHMED (China) Limited, a biopharmaceutical company listed on the stock exchange under the ticker symbol HCM. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with relapsed/refractory diffuse large B-cell lymphoma.
HMPL-760 planned dose 1 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The ongoing Phase 2 trial is evaluating the drug in patients with relapsed/refractory diffuse large B-cell lymphoma.
HMPL-760 planned dose 1 is being studied in a Phase 2 clinical trial with the identifier NCT06601504. The trial is titled "Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL" and is currently active but not recruiting participants. The study plans to enroll 61 patients with relapsed/refractory diffuse large B-cell lymphoma.
HMPL-760 planned dose 1 is a specific dose level of the investigational drug HMPL-760. The name "planned dose 1" indicates a particular dose being evaluated in clinical trials. HMPL-760 is the drug substance being developed by HUTCHMED for the treatment of relapsed/refractory diffuse large B-cell lymphoma.